CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
22.17
1.95%
Market Trading Hours* (UTC) Opens on Friday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.17
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-1.05)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.16)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 22.61
Open* 22.48
1-Year Change* -16.89%
Day's Range* 21.91 - 22.61
52 wk Range 27.65-111.48
Average Volume (10 days) 1.03M
Average Volume (3 months) 22.13M
Market Cap 5.13B
P/E Ratio -100.00K
Shares Outstanding 102.44M
Revenue 430.76M
EPS -5.94
Dividend (Yield %) N/A
Beta 0.62
Next Earnings Date Feb 21, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 22, 2024 22.17 -0.12 -0.54% 22.29 22.72 21.86
Feb 21, 2024 22.61 0.28 1.25% 22.33 22.64 21.87
Feb 20, 2024 22.79 1.06 4.88% 21.73 22.79 21.58
Feb 16, 2024 22.36 0.82 3.81% 21.54 22.66 21.45
Feb 15, 2024 22.04 0.15 0.69% 21.89 22.72 20.73
Feb 14, 2024 21.92 0.24 1.11% 21.68 22.39 21.43
Feb 13, 2024 21.28 -0.05 -0.23% 21.33 22.08 21.06
Feb 12, 2024 23.17 1.31 5.99% 21.86 23.31 21.85
Feb 9, 2024 22.53 0.32 1.44% 22.21 22.71 22.12
Feb 8, 2024 22.32 0.64 2.95% 21.68 22.41 21.64
Feb 7, 2024 22.01 -0.22 -0.99% 22.23 22.49 21.88
Feb 6, 2024 22.39 1.77 8.58% 20.62 22.50 20.62
Feb 5, 2024 21.21 -0.31 -1.44% 21.52 21.76 21.20
Feb 2, 2024 22.11 0.60 2.79% 21.51 22.35 20.99
Feb 1, 2024 21.87 0.00 0.00% 21.87 22.13 21.43
Jan 31, 2024 21.85 -0.24 -1.09% 22.09 22.85 21.70
Jan 30, 2024 22.20 -1.42 -6.01% 23.62 23.87 22.19
Jan 29, 2024 23.95 1.08 4.72% 22.87 23.96 22.67
Jan 26, 2024 23.02 0.20 0.88% 22.82 23.24 22.22
Jan 25, 2024 22.57 -0.04 -0.18% 22.61 23.43 22.34

Guardant Health, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 449.538 373.653 286.73 214.375 90.639
Revenue 449.538 373.653 286.73 214.375 90.639
Cost of Revenue, Total 155.625 122.212 92.535 70.72 43.21
Gross Profit 293.913 251.441 194.195 143.655 47.429
Total Operating Expense 999.216 759.654 541.68 296.746 179.331
Selling/General/Admin. Expenses, Total 463.784 398.521 299.283 139.734 89.657
Research & Development 373.807 263.221 149.862 86.292 50.714
Unusual Expense (Income) 5.3 -25 0 0 -4.25
Operating Income -549.678 -386.001 -254.95 -82.371 -88.692
Interest Income (Expense), Net Non-Operating -4.308 1.353 4.905 12.56 4.415
Other, Net -99.463 0.178 4.141 0.088 0.052
Net Income Before Taxes -653.449 -384.47 -245.904 -69.723 -84.225
Net Income After Taxes -654.588 -384.77 -246.283 -67.851 -84.263
Net Income Before Extra. Items -654.588 -405.67 -253.783 -75.651 -85.063
Total Extraordinary Items 0 0 0
Net Income -654.588 -405.67 -253.783 -75.651 -85.063
Total Adjustments to Net Income 0 0
Income Available to Common Excl. Extra. Items -654.588 -405.67 -253.783 -75.651 -85.063
Income Available to Common Incl. Extra. Items -654.588 -405.67 -253.783 -75.651 -85.063
Diluted Net Income -654.588 -405.67 -253.783 -75.651 -85.063
Diluted Weighted Average Shares 102.178 101.314 97.504 90.597 85.8325
Diluted EPS Excluding Extraordinary Items -6.40635 -4.00409 -2.6028 -0.83503 -0.99104
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -6.37263 -4.16448 -2.53809 -0.83503 -1.02322
Minority Interest 0 -20.9 -7.5 -7.8 -0.8
Other Operating Expenses, Total 0.7 0.7
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 137.15 128.714 126.891 117.404 109.144
Revenue 137.15 128.714 126.891 117.404 109.144
Cost of Revenue, Total 53.848 53.073 47.121 40.496 36.727
Gross Profit 83.302 75.641 79.77 76.908 72.417
Total Operating Expense 280.366 268.269 273.01 267.304 239.465
Selling/General/Admin. Expenses, Total 112.559 116.568 119.311 121.491 117.283
Research & Development 90.359 93.128 106.578 100.017 85.455
Unusual Expense (Income) 23.6 5.5 0 5.3
Operating Income -143.216 -139.555 -146.119 -149.9 -130.321
Interest Income (Expense), Net Non-Operating 70.082 6.316 6.906 -12.09 0.742
Other, Net 0.859 -0.054 -0.119 0.111 -99.407
Net Income Before Taxes -72.275 -133.293 -139.332 -161.879 -228.986
Net Income After Taxes -72.771 -133.533 -139.934 -161.994 -229.432
Minority Interest 0 0 0
Net Income Before Extra. Items -72.771 -133.533 -139.934 -161.994 -229.432
Net Income -72.771 -133.533 -139.934 -161.994 -229.432
Income Available to Common Excl. Extra. Items -72.771 -133.533 -139.934 -161.994 -229.432
Income Available to Common Incl. Extra. Items -72.771 -133.533 -139.934 -161.994 -229.432
Diluted Net Income -72.771 -133.533 -139.934 -161.994 -229.432
Diluted Weighted Average Shares 108.808 102.663 102.517 102.289 102.047
Diluted EPS Excluding Extraordinary Items -0.6688 -1.30069 -1.36498 -1.58369 -2.2483
Diluted Normalized EPS -0.52782 -1.26587 -1.36498 -1.55001 -2.2483
Dividends per Share - Common Stock Primary Issue 0 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1191.59 1114.13 1888.36 597.358 468.991
Cash and Short Term Investments 1011.23 932.748 1794.88 522.802 418.961
Cash & Equivalents 141.647 492.202 832.977 143.228 140.544
Short Term Investments 869.584 440.546 961.903 379.574 278.417
Total Receivables, Net 97.256 97.652 53.299 47.986 35.69
Accounts Receivable - Trade, Net 97.256 97.652 53.299 47.986 35.69
Total Inventory 51.598 30.674 22.716 15.181 9.136
Prepaid Expenses 31.509 53.052 17.466 11.389 5.204
Other Current Assets, Total 0
Total Assets 1609.98 2204.5 2271.78 962.535 587.403
Property/Plant/Equipment, Total - Net 341.921 313.904 100.125 72.808 31.003
Property/Plant/Equipment, Total - Gross 430.052 368.728 134.47 94.731 47.637
Accumulated Depreciation, Total -88.131 -54.824 -34.345 -21.923 -16.634
Long Term Investments 0 698.034 246.597 268.783 77.563
Other Long Term Assets, Total 61.453 60.938 17.253 11.772 9.846
Total Current Liabilities 193.22 194.687 66.809 72.734 46.944
Accounts Payable 68.911 17.58 7.34 16.197 10.642
Accrued Expenses 106.906 83.558 46.285 41.21 18.597
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.097
Other Current Liabilities, Total 17.403 93.549 13.184 15.327 17.608
Total Liabilities 1549.81 1559.49 973.286 164.142 104.251
Total Long Term Debt 1137.39 1134.82 806.292 0 0.119
Long Term Debt 1137.39 1134.82 806.292
Capital Lease Obligations 0.119
Other Liabilities, Total 219.194 229.986 43.085 41.808 15.388
Total Equity 60.18 645.005 1298.49 798.393 483.152
Preferred Stock - Non Redeemable, Net 0
Common Stock 0.001 0.001 0.001 0.001 0.001
Additional Paid-In Capital 1742.11 1657.59 1902.39 1150.09 764.033
Retained Earnings (Accumulated Deficit) -1662.41 -1007.83 -606.592 -352.809 -280.799
Unrealized Gain (Loss) -19.522 -4.764 2.697 1.111 -0.083
Total Liabilities & Shareholders’ Equity 1609.98 2204.5 2271.78 962.535 587.403
Total Common Shares Outstanding 102.619 100.214 100.214 94.2614 85.8325
Minority Interest 0 57.1 49.6 41.8
Goodwill, Net 3.29 3.29 3.29 3.29
Intangibles, Net 11.727 14.207 16.155 8.524
Redeemable Preferred Stock 0 0 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 1346.9 1397.66 1104.46 1191.59 1130.85
Cash and Short Term Investments 1154.82 1224.85 937.02 1011.23 958.037
Cash & Equivalents 457.339 271.073 223.64 141.647 158.31
Short Term Investments 697.482 953.776 713.38 869.584 799.727
Total Receivables, Net 88.801 86.468 87.204 97.256 86.2
Accounts Receivable - Trade, Net 88.801 86.468 87.204 97.256 86.2
Total Inventory 77.036 60.529 46.474 51.598 63.047
Prepaid Expenses 26.239 25.809 33.762 31.509 23.565
Total Assets 1797.23 1840.02 1511.63 1609.98 1701.78
Property/Plant/Equipment, Total - Net 309.339 321.014 333.88 341.921 346.754
Property/Plant/Equipment, Total - Gross 426.993 428.483 431.632 430.052 425.377
Accumulated Depreciation, Total -117.654 -107.469 -97.752 -88.131 -78.623
Goodwill, Net 3.29 3.29 3.29 3.29 3.29
Intangibles, Net 9.67 10.361 11.047 11.727 12.417
Long Term Investments 0 156.741
Other Long Term Assets, Total 128.035 107.697 58.954 61.453 51.728
Total Current Liabilities 226.751 200.933 204.155 193.22 175.124
Accounts Payable 77.828 79.784 67.32 68.911 40.911
Accrued Expenses 127.438 108.912 123.214 106.906 117.226
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 21.485 12.237 13.621 17.403 16.987
Total Liabilities 1568.93 1547.29 1556.18 1549.81 1535.03
Total Long Term Debt 1139.32 1138.68 1138.03 1137.39 1136.75
Long Term Debt 1139.32 1138.68 1138.03 1137.39 1136.75
Minority Interest
Other Liabilities, Total 202.859 207.68 213.993 219.194 223.162
Total Equity 228.299 292.726 -44.551 60.18 166.745
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.001 0.001 0.001 0.001 0.001
Additional Paid-In Capital 2188.8 2169.91 1763.54 1742.11 1716.07
Retained Earnings (Accumulated Deficit) -1954.82 -1868.72 -1795.95 -1662.41 -1522.48
Unrealized Gain (Loss) -5.68 -8.469 -12.15 -19.522 -26.852
Total Liabilities & Shareholders’ Equity 1797.23 1840.02 1511.63 1609.98 1701.78
Total Common Shares Outstanding 117.849 117.662 102.708 102.619 102.414
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -654.588 -384.77 -246.283 -67.851 -84.263
Cash From Operating Activities -309.463 -209.017 -103.927 -47.134 -72.185
Cash From Operating Activities 35.962 22.271 16.065 11.411 7.136
Non-Cash Items 247.599 193.95 173.956 15.398 6.069
Cash Taxes Paid 1.331 0.393 0.331 0.298 0.102
Cash Interest Paid 0 0 1.181 1.251
Changes in Working Capital 61.564 -40.468 -47.665 -6.092 -1.127
Cash From Investing Activities 149.816 -63.155 -617.086 -317.57 -153.028
Capital Expenditures -77.461 -75.035 -54.059 -21.217 -20.203
Other Investing Cash Flow Items, Total 227.277 11.88 -563.027 -296.353 -132.825
Cash From Financing Activities -189.093 -66.824 1410.31 367.304 293.161
Issuance (Retirement) of Stock, Net 11.941 17.865 372.353 368.466 256.99
Issuance (Retirement) of Debt, Net -0.071 -0.93 1132.58 -0.128 -0.443
Net Change in Cash -350.34 -340.689 689.749 2.684 67.948
Financing Cash Flow Items -200.963 -83.759 -94.622 -1.034 36.614
Foreign Exchange Effects -1.6 -1.693 0.455 0.084
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -133.533 -654.588 -514.654 -352.66 -123.228
Cash From Operating Activities -74.441 -309.463 -218.714 -140.554 -28.619
Cash From Operating Activities 10.345 35.962 25.793 15.986 7.201
Non-Cash Items 30.543 247.599 220.162 173.234 37.25
Cash Taxes Paid
Cash Interest Paid
Changes in Working Capital 18.204 61.564 49.985 22.886 50.158
Cash From Investing Activities 157.224 149.816 79.189 37.915 110.808
Capital Expenditures -7.524 -77.461 -67.46 -45.734 -22.7
Other Investing Cash Flow Items, Total 164.748 227.277 146.649 83.649 133.508
Cash From Financing Activities -0.854 -189.093 -191.411 -172.099 -0.012
Financing Cash Flow Items -0.993 -200.963 -199.605 -179.964 -0.957
Issuance (Retirement) of Stock, Net 0.157 11.941 8.247 7.9 0.963
Issuance (Retirement) of Debt, Net -0.018 -0.071 -0.053 -0.035 -0.018
Foreign Exchange Effects -0.163 -1.6 -2.74 -2.211 -0.792
Net Change in Cash 81.766 -350.34 -333.676 -276.949 81.385
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.1604 10781036 1567989 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 7.0517 8299348 661947 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 6.4655 7609327 2963721 2023-06-30 LOW
AllianceBernstein L.P. Investment Advisor/Hedge Fund 3.7927 4463669 1161901 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 3.4865 4103367 2522375 2023-06-30 LOW
Eventide Asset Management, LLC Investment Advisor 3.406 4008602 2133582 2023-06-30 LOW
Temasek Holdings Pte. Ltd. Sovereign Wealth Fund 3.368 3963872 299510 2023-06-30 LOW
Capital International Investors Investment Advisor 2.4598 2895044 -4329827 2023-06-30 LOW
Point72 Asset Management, L.P. Hedge Fund 2.3063 2714285 2714285 2023-06-30 HIGH
Millennium Management LLC Hedge Fund 2.0683 2434178 1136756 2023-06-30 HIGH
Talasaz (AmirAli) Individual Investor 2.0576 2421645 48500 2023-04-17 LOW
Eltoukhy (Helmy A) Individual Investor 2.052 2415013 0 2023-04-17 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.9961 2349257 775806 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9203 2260043 790085 2023-06-30 LOW
Credit Suisse Funds AG Investment Advisor/Hedge Fund 1.8622 2191721 43879 2023-06-30 LOW
Fidelity International Investment Advisor 1.7462 2055099 623203 2023-06-30 LOW
ClearBridge Investments, LLC Investment Advisor/Hedge Fund 1.6574 1950659 -752989 2023-06-30 LOW
Two Sigma Investments, LP Hedge Fund 1.499 1764248 575094 2023-06-30 HIGH
Capital World Investors Investment Advisor 1.4405 1695327 1695327 2023-09-30 LOW
Capital Research Global Investors Investment Advisor 1.4362 1690281 690281 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Guardant Health Company profile

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Industry: Bio Diagnostics & Testing

3100 Hanover Street
PALO ALTO
CALIFORNIA 94304
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

Oil - Crude

78.08 Price
-0.310% 1D Chg, %
Long position overnight fee 0.0161%
Short position overnight fee -0.0380%
Overnight fee time 22:00 (UTC)
Spread 0.030

XRP/USD

0.55 Price
-1.070% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

51,329.65 Price
-0.710% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

17,996.00 Price
+0.110% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading